AI is becoming an increasingly important accelerant for life sciences innovation, helping researchers develop new therapies, improve diagnostics and better understand human biology.

In this Amati Insights discussion, Amati fund managers Mikhail Zverev and Graeme Bencke explain why the next phase of AI adoption in healthcare may benefit the entire life sciences value chain. They explore the growing role of laboratory automation, drug discovery platforms, clinical trials, healthcare data, diagnostics and research tools, and discuss the investment implications of this emerging "Lab in the Loop" ecosystem.

Warning: Capital at Risk. Professional Investors Only.